Healthcare

Immutep Limited (ASX:IMM)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.5350.005 (0.943%)

(as on 2021-09-26 10:27:25)

Market Cap : AUD 400.262 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.53 0.53 0.535 0.53L 0.54 H 0.23L 0.725 H
Last Trade 0.535
Change% 0.9434
52 W H/L 0.725/0.23
EBITDA -25.187 M
NPAT After Abnormal Items -29.903 M
Equity 73.272 M
ROE% -40.81%
Total Liabilities 8.759 M
Total Revenue 3.863 M
Cash and Cash Equivalents 60.593 M

Stock Information

Share price 0.535
Market Cap 400.262 M
Price/Gross Cash Flow -21.74
Dividend Yield Excluding Special 0.00%
Ending Shares 748.153 M
52-Week Range 0.23-0.725
P/E ratio 0.000
Sector P/E --
EPS -5.03
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.03
Net Gearing -78.85%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.08
Sales Per Share 0.00
Book Value Per Share 0.10

Announcements

Heading Date/Time
Immutep to present final AIPAC Overall Survival data at SITC  21/09/2021 6:38PM
Recruitment of patients completed for Part B of TACTI-002  01/09/2021 10:07AM
Immutep's partner, EOC Pharma, expands efti trial pipeline  31/08/2021 8:46AM
Appendix 4E & 2021 Full Year Statutory Accounts  30/08/2021 7:08PM
Chinese patent granted for anti-LAG-3 antibody LAG525  27/08/2021 8:04AM
INSIGHT-003 investigator-initiated trial - 1st patient dosed  05/08/2021 8:18AM
Becoming a substantial holder  03/08/2021 7:18PM
Change in substantial holding  03/08/2021 8:21AM
Cleansing Notice  30/07/2021 10:03AM
Completion of Placement - Tranche 2  30/07/2021 9:24AM
Application for quotation of securities - IMM  29/07/2021 8:22AM
Change in substantial holding  27/07/2021 8:19AM
Proposed issue of securities - IMM  27/07/2021 8:15AM
Results of EGM  26/07/2021 6:37PM
Chairman's EGM Address  26/07/2021 12:04PM
2021 EGM Presentation  26/07/2021 11:56AM
Application for quotation of securities - IMM  23/07/2021 8:25AM
Change in substantial holding  23/07/2021 8:25AM
Completion of Share Purchase Plan  21/07/2021 9:00AM
EGM - Now to be Held as an Online Virtual Meeting  15/07/2021 1:10PM
Immutep Quarterly Activities Report & Appendix 4C  13/07/2021 9:48AM
US FDA & IRB approves start of ph2b head & neck cancer trial  06/07/2021 8:58AM
Proposed issue of securities - IMM  05/07/2021 4:34PM
Change in substantial holding from AEF  30/06/2021 12:28PM
Change in substantial holding  30/06/2021 8:19AM
Cleansing Notice  28/06/2021 8:11AM
Notice of Extraordinary General Meeting/Proxy Form  25/06/2021 4:15PM
Share Purchase Plan Offer Documents  25/06/2021 4:04PM
Application for quotation of securities - IMM  25/06/2021 11:39AM

Similar Companies

Related Articles

About Company

Immutep Ltd (ASX: IMM) is a biotechnology company that has been working in the field of developing immunotherapy treatments for cancer and autoimmune diseases; and the group is now focused on leveraging its technology and expertise in bringing new and innovative treatments and solutions to the market for patients. IMM aims to provide good shareholder value through the development of its flagship products.

Corporate Information

company address Level 12, 95 Pitt Street, SYDNEY, NSW, AUSTRALIA, 2000

company phone+61 2 8315 7003

company websitehttp://www.immutep.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-29 2022
Report (Prelim) 2022-08-29 2022
Report (Interim) 2022-02-22 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- 7.486 M 139,782 2.63 M --
Other Revenue 3.863 M 8.814 M 6.952 M 4.546 M 4.117 M
Total Revenue 3.863 M 16.3 M 7.092 M 7.176 M 4.117 M
Interest Income 105,327 199,541 397,281 177,186 104,368
Interest Expenses -9,825 -10,457 0 0 0
Expenses -31.791 M -27.878 M -23.954 M -18.289 M -12.625 M
EBITDA -27.928 M -11.578 M -16.862 M -11.113 M -8.507 M
Depreciation and Amortization -2.07 M -2.08 M -1.879 M -1.809 M -1.702 M
Depreciation -204,049 -149,263 -15,499 -10,624 -13,941
Amortisation -1.866 M -1.93 M -1.864 M -1.798 M -1.688 M
EBIT -29.998 M -13.657 M -18.741 M -12.922 M -10.209 M
Pre Tax Profit -29.903 M -13.468 M -18.344 M -12.744 M -10.105 M
Tax Expense -33 -37 0 -1,676 737,387
Net Profit After Tax -29.903 M -13.468 M -18.344 M -12.746 M -9.367 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items -29.903 M -13.468 M -18.344 M -12.746 M -9.367 M
Ending Shares 748.153 M 487.631 M 341.18 M 304.68 M 209.398 M
Weighted Average Shares 594.927 M 400.98 M 324.766 M 262.619 M 208.664 M
EPS After Abnormal Items (cents) -5.03 -3.36 -5.65 -4.85 -4.49
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 68.419 M 31.152 M 23.542 M 28.643 M 15.919 M
Total Non Current Assets 13.611 M 15.445 M 17 M 18.356 M 19.045 M
Total Assets 82.031 M 46.597 M 40.541 M 46.999 M 34.964 M
Total Current Liabilities 5.34 M 3.364 M 5.299 M 3.853 M 2.632 M
Total Non Current Liabilities 3.419 M 9.934 M 10.855 M 9.623 M 5.799 M
Total Liabilities 8.759 M 13.298 M 16.154 M 13.477 M 8.431 M
Net Assets 73.272 M 33.299 M 24.388 M 33.522 M 26.532 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -17.64 M -10.839 M -15.286 M -7.777 M -8.507 M
Net Invested Cash -15,601 -19,348 -41,434 -11,893 -6,644
Net Financing Cash Flows 52.68 M 20.478 M 8.013 M 18.405 M -8,532
End Cash Position 60.593 M 26.322 M 16.568 M 23.476 M 12.237 M
Beginning Cash 26.322 M 16.568 M 23.476 M 12.237 M 20.88 M
Exchange Rate Adjustments -752,838 134,671 407,578 622,576 -120,600
Other Cash Adjustments 0 0 0 0 0
Ending Cash 60.593 M 26.322 M 16.568 M 23.476 M 12.237 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK